407
Views
1
CrossRef citations to date
0
Altmetric
Other Disease

Atopic dermatitis 2017: where we were 10–15 years ago in psoriasis

, , ORCID Icon, &
Pages 100-101 | Received 14 Feb 2017, Accepted 08 May 2017, Published online: 30 Jun 2017
 

Abstract

Novel and innovative treatment options for atopic dermatitis (AD) are underway. The recent advancements in understanding AD are reminiscent of the progress made in psoriasis research over a decade ago.

Disclosure statement

Dr. Wu is an investigator for AbbVie, Amgen, Eli Lilly, Janssen, Novartis, and Regeneron.

Dr. Egeberg has received research funding from Pfizer and Eli Lilly, and honoraria as consultant and/or speaker from Pfizer, Eli Lilly, Novartis, Galderma and Janssen Pharmaceuticals.

Dr. Thyssen is supported by an unrestricted grant from the Lundbeck Foundation and has attended an advisory board for Roche and Sanofi-Genzyme, and been a speaker on atopic dermatitis for LEO Pharma.

Mr. No and Ms. Amin do not have any potential conflicts of interest to report.

Additional information

Funding

This article has no funding source.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access
  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart
* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.